Table 1 (abstract O07). Assessment of drug response in the patients with colchicine resistant familial Mediterranean fever
| Â | Baseline (n=114) | 1st month (n=114) | 3rd month (n=114) | 6th month (n=114) | 12th month (n=114) | 18th month (n=114) | 24th month (n=114) |
|---|---|---|---|---|---|---|---|
PGA* | 8 (5-10) | 1 (0-10) | 0 (0-5) | 0 (0-5) | 0 (0-3) | 0 (0-5) | 0 (0-3) |
CRP* | 16.2 (11-31) | 0.65 (0.02-58.6) | 0.2 (0-15.8) | 0.7 (0-68) | 0.5 (0-24.9) | 0.3 (0-41) | 0.3 (0.16.1) |
SAA* | 89 (2.9-1870) | 3.9 (0-17) | 4 (0-23) | 3.3 (0-70) | 3.6 (0-152) | 3 (0-42) | 3 (0-24) |
Dose interval of CAN (weeks) | 4 (4-8) 4 weeks in 94 8 weeks in 20 | 4 (4-8) 4 weeks in 94 8 weeks in 20 | 4 (4-8) 4 weeks in 94 8 weeks in 20 | 6 (4-8) 4 weeks in 66 6 weeks in 21 8 weeks in 27 | 6 (4-8) 4 weeks in 50 6 weeks in 21 8 weeks in 41 12 weeks in 2 | 8 (4-12) 4 weeks in 45 6 weeks in 21 8 weeks in 40 12 weeks in 3 No drug in 5 | 8 (4-12) 4 weeks in 39 6 weeks in 25 8 weeks in 38 No drug in 12 |
Dosage of CAN (mg/kg) | 2-4 mg/kg | 2-4 mg/kg | 2-4 mg/kg | 2-4 mg/kg | 2-4 mg/kg | 2-4 mg/kg | 2-4 mg/kg |
Number of patients experienced attacks | NA | 0 | 2 | 1 | 5 | 4 | 2 |
Number of patients requiring higher dose or shortening drug interval | NA | 0 | 2 (recurrent attacks) | 0 | 2 (recurrent attacks) | 4 (recurrent attacks) (shortened from 8Â to 6 weeks | 2 (recurrent attacks, CAN was restarted) |
Number of patients whose prolonged drug interval | NA | 0 | 7 patients (prolonged from 4 to 8 weeks) 21 patients (prolonged from 4 to 6 weeks) | 16 patients (prolonged from 4 to 8 weeks) 2 patients (prolonged from 8 to 12 weeks) | 5 patients (prolonged from 4 to 8 weeks) 1 patient (prolonged from 8 to 12 weeks) | 6 patients (prolonged from 4 to 8 weeks) | NA |
Number of patients discontinued CAN | 0 | 0 | 0 | 0 | 5 patients | 7 patients | 0 |
Number of infections | NA | 1 (pneumonia) | 1 (upper respiratory tract infection) | 0 | 0 | 0 | 2 (upper respiratory tract infection) |
Number of adverse event | NA | 0 | 0 | 0 | 0 | 0 | 0 |